Core Viewpoint - The company reported a revenue of approximately 1.285 billion yuan for 2024, marking an 8.2% year-on-year increase, driven by sales growth in hepatitis B, hepatitis A, and quadrivalent meningococcal vaccines [1] Financial Performance - Revenue for 2024 was approximately 1.285 billion yuan, up 8.2% year-on-year - Gross profit was about 953.5 million yuan, reflecting a 5.8% increase year-on-year - Net loss narrowed to approximately 278 million yuan, a reduction of 85.7% year-on-year - Net cash inflow from operating activities was nearly 100 million yuan [1] Research and Development - R&D expenditure was 363 million yuan, down 42.9% year-on-year, primarily due to reduced overseas clinical trial costs - The company has completed Phase III clinical trial site work for its serum-free rabies vaccine and 23-valent pneumococcal polysaccharide vaccine, with the former already submitted for market registration [1] - The company is actively pursuing international market registrations for its products in Southeast Asia, Africa, South America, and the Middle East [1] Product Pipeline and Market Strategy - The company is advancing its product pipeline in line with international market demands, focusing on high-priority vaccines such as the 13-valent pneumococcal conjugate vaccine and quadrivalent meningococcal conjugate vaccine [2] - The company is also developing vaccines for respiratory syncytial virus and shingles, which are in high demand in international markets [2] - Existing products like hepatitis A, hepatitis B, and rabies vaccines are prioritized by the World Health Organization and are well-received in international markets [2] Production Capacity - The GMP workshops for iterative pneumonia and rabies vaccines have been completed in phases, meeting international standards - Clinical trial samples and process validation samples for the 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, and serum-free rabies vaccine are produced in these workshops, ensuring readiness for international market entry [3]
艾美疫苗(06660)2024年实现收入约12.85亿元 同比增长8.2% 创新管线全面突破